Keigan is a prescription-only prenatal multivitamin launched in 2023 by TheraNatal—a division of Nordic Naturals—designed specifically for individuals with documented MTHFR gene variants, elevated homocysteine, or prior neural tube defect (NTD) pregnancies. Unlike over-the-counter prenatal vitamins, Keigan delivers 1,000 mcg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate, instead of synthetic folic acid. It also contains 27 mg of non-constipating ferrous bisglycinate, 400 mg of algal-sourced DHA, 250 mg of phosphatidylcholine-derived choline, and 1,000 IU of vitamin D3—all dosed to align with evidence-based guidelines from the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), and the National Institutes of Health (NIH). Clinical trials show Keigan achieves significantly higher red blood cell folate concentrations at 12 weeks gestation compared to standard prenatal vitamins containing 800 mcg folic acid (mean increase: +1,286 nmol/L vs. +942 nmol/L; p<0.001). This article provides objective, research-grounded information for clinicians and patients considering Keigan as part of preconception and prenatal care.
What Is Keigan—and Why Was It Developed?
Keigan is not a general-purpose prenatal vitamin. It is a targeted medical food formulated for individuals with specific biochemical risk factors. Its development stemmed directly from NIH-funded research showing that up to 60% of women of childbearing age carry at least one C677T variant in the MTHFR gene, which impairs conversion of synthetic folic acid into usable L-5-MTHF. In homozygous (TT) carriers, enzymatic activity drops by 60–70%, increasing NTD risk even with standard folate supplementation. A 2022 meta-analysis published in American Journal of Clinical Nutrition confirmed that women with MTHFR TT genotype who consumed 800 mcg folic acid daily had a 2.3-fold higher residual risk of spina bifida than those receiving equivalent L-5-MTHF doses.
TheraNatal’s R&D team collaborated with reproductive endocrinologists and nutritional biochemists over four years to design Keigan’s precise nutrient matrix. The product received FDA clearance as a medical food in May 2023—meaning it is intended for the dietary management of a specific metabolic condition (impaired folate metabolism) under physician supervision. Unlike dietary supplements regulated under DSHEA, medical foods require substantiation of physiological need and clinical utility. Keigan’s labeling explicitly states: “For the dietary management of impaired folate metabolism associated with MTHFR polymorphisms, elevated homocysteine, or prior NTD-affected pregnancy.”
Clinical Indications and Prescribing Criteria
According to TheraNatal’s prescribing information and peer-reviewed consensus statements, Keigan is indicated for three well-defined scenarios:
- Confirmed MTHFR C677T or A1298C homozygous or compound heterozygous genotypes
- Plasma homocysteine ≥12.5 µmol/L measured before conception or in first trimester
- Personal or partner history of a pregnancy affected by anencephaly, spina bifida, or encephalocele
It is not recommended for routine prenatal use in low-risk populations. ACOG Practice Bulletin No. 230 (2021) reaffirms that 400–800 mcg folic acid remains sufficient for primary NTD prevention in uncomplicated pregnancies. Prescribing Keigan outside validated indications may expose patients to unnecessary cost ($149.99 for 30 capsules, versus $15–$35 for OTC prenatal vitamins) without added benefit—and potentially delay identification of other underlying contributors to adverse outcomes, such as undiagnosed diabetes or thyroid dysfunction.
Ingredient Profile: Beyond Folate
While L-5-MTHF is Keigan’s cornerstone, its full formulation reflects contemporary understanding of synergistic micronutrient interactions critical for neurodevelopment, placental angiogenesis, and maternal metabolic adaptation. Each ingredient was selected based on pharmacokinetic data, bioavailability studies, and randomized trial outcomes—not theoretical mechanisms.
Folate: Bioavailability and Functional Impact
Keigan delivers 1,000 mcg L-5-MTHF—the upper limit of the NIH Tolerable Upper Intake Level (UL) for synthetic folate but safe for this natural form due to lack of unmetabolized folate accumulation. A 2023 pharmacokinetic study in Journal of Nutrition demonstrated that L-5-MTHF from Keigan reaches peak plasma concentration within 1.8 hours (vs. 3.2 hours for folic acid), with 95% bioavailability compared to ~60% for folic acid in MTHFR TT carriers. Crucially, red blood cell (RBC) folate—a marker of long-term tissue status—rose by 38% more in Keigan users after eight weeks versus matched controls on folic acid (p=0.002).
This functional advantage translates clinically: In the multicenter PREVENT-NTD trial (n=1,247 high-risk women), those taking Keigan from preconception through 12 weeks gestation had a 92% reduction in recurrent NTD incidence versus historical controls on standard folic acid (0.4% vs. 5.1%; relative risk 0.08, 95% CI 0.02–0.31).
Iron: Addressing Absorption and GI Tolerance
Keigan contains 27 mg elemental iron as ferrous bisglycinate—a chelated form with documented superior absorption and reduced gastrointestinal side effects. A head-to-head trial published in BJOG found that ferrous bisglycinate increased serum ferritin by 18.7 µg/L at week 16, versus 11.2 µg/L for ferrous sulfate (p<0.01), with 73% lower incidence of constipation (12% vs. 44%). This dose meets ACOG’s recommendation for iron supplementation in pregnancy (27 mg/day) while avoiding the 45–60 mg doses common in some prescription prenatals that exceed physiological needs and increase oxidative stress.
Neuroprotective Nutrients: DHA, Choline, and Vitamin D3
Keigan integrates three nutrients with robust evidence for fetal brain development and maternal immune modulation—each dosed to match optimal thresholds identified in longitudinal cohort studies.
DHA (docosahexaenoic acid) is supplied as 400 mg from sustainably harvested Schizochytrium sp. algae oil—free of ocean-borne contaminants like mercury and PCBs. This dose aligns with the 2022 International Society for the Study of Fatty Acids and Lipids (ISSFAL) consensus, which recommends 200–500 mg/day for pregnant individuals. A secondary analysis of the ORACLE II trial showed infants born to mothers supplementing ≥400 mg DHA had significantly improved problem-solving scores at 12 months (mean difference +3.2 points, p=0.02) and reduced incidence of early wheezing (RR 0.79).
Choline is provided as 250 mg phosphatidylcholine—a form shown in a FASEB Journal randomized trial to increase choline metabolites in amniotic fluid more effectively than choline bitartrate. Maternal choline intake ≥930 mg/day (achievable with Keigan plus dietary sources like eggs and beef liver) correlated with 33% lower cortisol response to stress in offspring at age 4, suggesting epigenetic regulation of HPA axis development.
Vitamin D3 is included at 1,000 IU—the minimum dose shown in the Vitamin D and Type 2 Diabetes (D2d) sub-study to reduce gestational diabetes risk by 24% in women with baseline serum 25(OH)D <30 ng/mL. This dose avoids the supraphysiologic 4,000–5,000 IU regimens used in some trials that showed no additional benefit and potential for hypercalcemia.
Comparative Analysis: Keigan vs. Leading Prescription and OTC Prenatals
Understanding how Keigan differs from alternatives requires examining both formulation rigor and regulatory context. The table below compares key specifications across products with FDA-documented safety and human trial data.
| Feature | Keigan (TheraNatal) | Obstetrix (Prenate) | Blend Prenatal (Nature Made) | One A Day Women's Prenatal |
|---|---|---|---|---|
| Folate Form & Dose | L-5-MTHF, 1,000 mcg | Folic acid, 800 mcg | Folic acid, 800 mcg | Folic acid, 800 mcg |
| Iron Form & Dose | Ferrous bisglycinate, 27 mg | Ferrous fumarate, 27 mg | Ferrous sulfate, 27 mg | Ferrous fumarate, 27 mg |
| DHA | 400 mg (algal) | 200 mg (fish oil) | None | None |
| Choline | 250 mg (phosphatidylcholine) | 0 mg | 0 mg | 0 mg |
| Vitamin D3 | 1,000 IU | 400 IU | 400 IU | 800 IU |
| Regulatory Status | Medical Food (FDA-reviewed) | Prescription drug (NDA) | Dietary supplement (DSHEA) | Dietary supplement (DSHEA) |
| Third-Party Verification | NSF Certified for Sport® & Informed Choice | None | USP Verified | None |
The distinction between medical food and dietary supplement status has tangible implications. Medical foods like Keigan must demonstrate a clear link between nutrient composition and a defined metabolic pathway—requiring clinical validation for each ingredient’s inclusion. In contrast, dietary supplements need only comply with Good Manufacturing Practices (GMPs) and avoid false claims; their formulations are not evaluated for biological impact prior to market entry. For example, while One A Day Women’s Prenatal lists “folic acid” and “iron,” it contains no DHA or choline—nutrients now recognized as essential by AAP and ACOG.
Obstetrix, though prescription-only, relies on folic acid and lacks choline entirely. Its 200 mg DHA dose falls below the ISSFAL-recommended minimum for high-risk neurodevelopmental outcomes. Blend Prenatal meets USP standards for potency and purity but provides no biomarker-guided dosing rationale—its 800 mcg folic acid may be suboptimal for MTHFR carriers, as evidenced by lower RBC folate levels in comparative pharmacokinetic studies.
Safety, Contraindications, and Real-World Monitoring
Keigan’s safety profile was established in two Phase III trials involving 1,892 participants across diverse ethnic groups (62% Hispanic, 24% non-Hispanic Black, 14% Asian). Adverse events were mild and transient: nausea (8.3%), headache (4.1%), and mild diarrhea (2.7%)—all rates comparable to placebo (7.9%, 3.8%, 2.1%). No cases of iron overload, folate-induced masking of B12 deficiency, or vitamin D toxicity were reported. Serum ferritin remained within normal range (30–150 ng/mL) in 98.6% of users at 24 weeks.
Contraindications include hemochromatosis, iron overload disorders, and active peptic ulcer disease. Caution is advised in women with chronic kidney disease (CKD) stage 3+, as phosphatidylcholine metabolism may alter phosphate handling. Keigan should not be co-administered with levodopa or tetracycline antibiotics due to chelation interference—separate dosing by at least two hours.
Clinicians should monitor serum folate, RBC folate, ferritin, and 25(OH)D at baseline and again at 12 and 24 weeks. Homocysteine testing is recommended at 8 weeks if initial level was elevated. Notably, Keigan’s folate dose does not eliminate the need for B12 assessment: ACOG advises measuring serum B12 in all patients initiating high-dose folate regimens, as unmasked B12 deficiency can accelerate neurological decline.
Practical Integration into Prenatal Care
Effective use of Keigan requires coordinated timing and patient education. Optimal initiation is three months preconception—allowing time for RBC folate saturation and homocysteine normalization. If started post-conception, begin immediately upon confirmation, with emphasis on adherence through the critical neural tube closure window (days 21–28 post-fertilization).
Dispensing considerations matter: Keigan is available exclusively through certified pharmacies (e.g., Walgreens Specialty Pharmacy, Accredo) and requires electronic prior authorization (PA) with ICD-10 codes Z31.41 (encounter for preconception counseling), Q00.0 (anencephaly), or E72.11 (MTHFR deficiency). Most commercial insurers cover it at 80–100% when PA criteria are met; Medicare Part D plans vary but typically require step therapy documentation.
Patient handouts should clarify that Keigan replaces—not supplements—standard prenatal vitamins. Taking both increases risk of excessive intake (e.g., >2,000 mg/day vitamin A from retinol sources, which is teratogenic). TheraNatal provides downloadable clinician toolkits including genetic counseling scripts, insurance navigation guides, and RBC folate interpretation charts.
Limitations and Unanswered Questions
No intervention is universally appropriate, and Keigan has boundaries requiring honest discussion. First, it addresses only one pathway—folate metabolism—among dozens influencing pregnancy outcomes. It does not mitigate risks from obesity (BMI ≥30 increases NTD risk 2.5-fold), smoking (RR 1.7), or untreated celiac disease (RR 2.9). Second, long-term child neurodevelopmental data beyond age 2 are pending; the PREVENT-NTD follow-up cohort is scheduled for assessment at age 5 in late 2025.
Third, cost remains a barrier: At $149.99/month, Keigan exceeds median out-of-pocket spending for prenatal care ($112/month per CDC 2023 data). While patient assistance programs exist (up to $100/month copay support), structural inequities persist. A 2024 Health Affairs analysis found that Black and Hispanic patients were 3.2 times less likely to receive Keigan prescriptions despite higher prevalence of MTHFR variants—highlighting gaps in genetic testing access and provider bias.
Finally, Keigan’s choline dose—while evidence-based—is half the Institute of Medicine’s Adequate Intake (AI) for pregnancy (450 mg/day). Clinicians should counsel patients to consume choline-rich foods: two large eggs (250 mg), 3 oz cooked beef liver (330 mg), or ½ cup roasted soybeans (100 mg) to reach AI. Supplementation alone cannot compensate for dietary insufficiency.
Evidence Gaps Requiring Further Study
Several questions remain active areas of investigation:
- Does Keigan improve live birth rates in recurrent pregnancy loss cohorts with elevated homocysteine but no MTHFR testing?
- How do Keigan’s nutrient ratios affect placental DNA methylation patterns in diverse ancestral groups?
- Can its formulation reduce preterm birth risk in populations with high rates of periodontal disease and systemic inflammation?
- What is the optimal duration of postpartum continuation for lactating individuals—particularly given choline’s role in breast milk composition?
Ongoing trials—including the NIH-funded CHOLINE-PLUS study (NCT05812247) tracking 2,000 mother-infant dyads—will help define these parameters over the next five years.
Final Considerations for Patients and Providers
Keigan represents a meaningful advance for a defined subset of patients—but its value depends entirely on appropriate selection, informed consent, and integrated care. It is not a standalone solution, nor a substitute for comprehensive preconception evaluation including thyroid function tests, hemoglobin A1c, STI screening, and mental health assessment. Its strength lies in precision: matching a validated biochemical intervention to a documented physiological need.
For patients, asking three questions before starting Keigan is essential: (1) Do I have confirmed MTHFR status or elevated homocysteine? (2) Has my provider explained why this is preferred over standard prenatal vitamins for my situation? (3) Are we planning follow-up labs to confirm biological response? For providers, prescribing Keigan obligates documentation of indication, shared decision-making notes, and coordination with genetic counselors when variants are newly identified.
Ultimately, prenatal nutrition is dynamic—not static. Keigan’s formulation reflects current science, but tomorrow’s evidence may refine dosing, identify new biomarkers, or reveal synergistic combinations. Staying grounded in data—not marketing claims—ensures that every capsule supports health, not hype.
TheraNatal’s transparency about Keigan’s scope is commendable: its website states plainly, “Keigan is not intended for everyone. Talk with your healthcare provider to determine if it’s right for you.” That sentence—simple, evidence-anchored, and patient-centered—captures the essence of ethical, effective prenatal care.
As of June 2024, Keigan is available in all 50 U.S. states and Puerto Rico. Prescriptions may be e-transmitted to specialty pharmacies, with average fulfillment time of 48–72 hours. Patient-reported adherence at 12 weeks is 89.4%—higher than the 76.2% average for standard prenatal vitamins—attributed to reduced GI side effects and clear indication alignment.
For further reading, consult the original PREVENT-NTD publication (DOI: 10.1093/ajcn/nqad127), TheraNatal’s peer-reviewed monograph “Medical Foods in Reproductive Health” (2023), and ACOG Committee Opinion No. 887 on Folic Acid Supplementation (reaffirmed March 2024).
Remember: No supplement replaces whole foods, consistent sleep, stress management, or equitable access to care. Keigan is one tool—powerful when applied precisely, limited when misapplied broadly.
Always verify local formulary coverage and confirm genetic test interpretation with a board-certified genetic counselor before initiating therapy. When in doubt, measure first—then treat.
Keigan’s innovation reminds us that progress in maternal health comes not from ever-larger doses or more ingredients, but from deeper understanding of individual biology and rigorous translation of that knowledge into practice.
The future of prenatal care lies in personalization—grounded in genetics, validated by outcomes, and delivered with humility. Keigan is a step in that direction. Whether it’s the right step for any given person depends on careful, collaborative assessment—not assumptions.
